Radcliff F J, Hazell S L, Kolesnikow T, Doidge C, Lee A
School of Microbiology and Immunology, The University of New South Wales, Sydney, Australia.
Infect Immun. 1997 Nov;65(11):4668-74. doi: 10.1128/iai.65.11.4668-4674.1997.
The efficacy of an orogastric vaccine comprised of purified Helicobacter pylori catalase plus the mucosal adjuvant cholera toxin (CT) was examined with both the Helicobacter felis and H. pylori mouse models with BALB/c mice. Native H. pylori catalase (200 microg) plus CT was initially used as a vaccine antigen in the H. felis mouse model and protected 80% (8 of 10) of the challenged animals, while all control animals were infected (20 of 20). In a follow-up experiment, recombinant H. pylori catalase plus CT was used for immunization, and groups of mice were challenged with the Sydney strain of H. pylori. Immunization with recombinant catalase protected a significant proportion (9 of 10) of the mice from H. pylori challenge, indicating that this enzyme should be considered as a candidate for a future vaccine. This study provides the first available data on the efficacy of protective immunization with the new Sydney strain of H. pylori in a mouse model. These data also provide indirect evidence that proteins which are normally intracellular, such as catalase, may be present on the surface of H. pylori and thus may provide targets for immunization.
利用幽门螺杆菌（Helicobacter pylori）感染的BALB/c小鼠模型，分别用猫幽门螺杆菌（Helicobacter felis）和幽门螺杆菌对一种由纯化的幽门螺杆菌过氧化氢酶加黏膜佐剂霍乱毒素（CT）组成的经口胃内疫苗的疗效进行了检测。天然幽门螺杆菌过氧化氢酶（200微克）加CT最初用作猫幽门螺杆菌小鼠模型中的疫苗抗原，保护了80%（10只中的8只）受攻击动物，而所有对照动物均被感染（20只中的20只）。在后续实验中，用重组幽门螺杆菌过氧化氢酶加CT进行免疫，然后用幽门螺杆菌悉尼菌株攻击小鼠组。用重组过氧化氢酶免疫可使相当比例（10只中的9只）的小鼠免受幽门螺杆菌攻击，表明该酶应被视为未来疫苗的候选物。本研究提供了关于新型幽门螺杆菌悉尼菌株在小鼠模型中进行保护性免疫疗效的首批可用数据。这些数据还间接证明，通常位于细胞内的蛋白质，如过氧化氢酶，可能存在于幽门螺杆菌表面，因此可能提供免疫靶点。
